A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

BACKGROUND: Patients with asthma uncontrolled on inhaled corticosteroids may benefit from umeclidinium (UMEC), a long-acting muscarinic antagonist. METHODS: This Phase IIb, double-blind study included patients with reversible, uncontrolled/partially-controlled asthma for ≥6 months, receiving ≥100 mc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerwin, Edward, Pascoe, Steven, Bailes, Zelie, Nathan, Robert, Bernstein, David, Dahl, Ronald, von Maltzahn, Robyn, Robbins, Kevin, Fowler, Andrew, Lee, Laurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291639/
https://www.ncbi.nlm.nih.gov/pubmed/32532275
http://dx.doi.org/10.1186/s12931-020-01400-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291639/
https://www.ncbi.nlm.nih.gov/pubmed/32532275
http://dx.doi.org/10.1186/s12931-020-01400-5

Ejemplares similares